{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:42:08Z","timestamp":1790890928225,"version":"4.1.0"},"reference-count":236,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"Systemic Lupus Erythematosus (SLE or lupus) is a chronic autoimmune disease characterized and driven by anti-nuclear antibodies, most prominently anti-double-stranded (ds) DNA IgGs. Lupus remains a serious clinical challenge largely because available medications lack specificity to lupus autoimmunity, unavoidably impairing normal immune responses and often harming other important body functions. Reinforcement of immune tolerance has a great potential for selective suppression of lupus autoimmunity. However, despite extensive efforts, satisfactory clinical outcomes have not yet been achieved. Here, we review relevant literature on the approaches that reinforce immune tolerance for lupus treatment and classify them into following categories based on their mechanisms of action: (1) directly blocking anti-dsDNA antibodies, (2) leveraging regulatory T cell-regulated B cell extrinsic tolerance, and (3) reinforcing B cell intrinsic tolerance. B cell intrinsic tolerance contains various \u201cbuilt-in\u201d self-protective mechanisms that prevent B cell autoimmunity. In lupus patients, impaired B cell intrinsic tolerance to lupus autoimmunity is a root cause of disease development. However, due to the poorly understood tolerance mechanisms, few publications have studied therapeutic approaches that restore B cell intrinsic tolerance to lupus autoimmunity for physiological suppression of disease. To facilitate the development of such approaches, this review concludes by emphasizing a discussion of B cell intrinsic tolerance to lupus autoimmunity, including our recent finding of a B cell intrinsic tolerance mechanism that was required to prevent lupus pathogenesis and could be pharmacologically restored to selectively suppress lupus autoimmunity in a preclinical model.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1728403","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:50:48Z","timestamp":1770792648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Restoring B cell intrinsic tolerance to lupus autoimmunity: a rational strategy for lupus treatment"],"prefix":"10.3389","volume":"17","author":[{"given":"Shreya Desikan","family":"Shai","sequence":"first","affiliation":[{"name":"State University of New York (SUNY) Downstate Health Sciences University, Program in Molecular and Cellular Biology, The School of Graduate Studies","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailee Vijay","family":"Chavan","sequence":"additional","affiliation":[{"name":"State University of New York (SUNY) Downstate Health Sciences University, Program in Molecular and Cellular Biology, The School of Graduate Studies","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Zi","family":"Huan","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, SUNY Downstate Health Sciences University","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Kalin","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, SUNY Downstate Health Sciences University","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Feuerman","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, SUNY Downstate Health Sciences University","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A. J.","family":"Roman","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, SUNY Downstate Health Sciences University","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongmin","family":"Huan","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, SUNY Downstate Health Sciences University","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/keac610","article-title":"The global epidemiology of SLE: narrowing the knowledge gaps","volume":"62","author":"Barber","year":"2023","journal-title":"Rheumatol (Oxford England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: A review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315627202","article-title":"Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190733","article-title":"Association between cigarette smoking and systemic lupus erythematosus: an updated multivariate bayesian metaanalysis","volume":"47","author":"Chua","year":"2020","journal-title":"J Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/ar4429","article-title":"Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus","volume":"16","author":"Hanlon","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/rheumatology\/keaa444","article-title":"Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus","volume":"60","author":"Morotti","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac613","article-title":"The impact of social determinants of health on the presentation, management and outcomes of systemic lupus erythematosus","volume":"62","author":"Williams","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.151","article-title":"Anti-DNA antibodies \u2014 quintessential biomarkers of SLE","volume":"12","author":"Pisetsky","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102861","article-title":"Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target","volume":"132","author":"Lou","year":"2022","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313492872","article-title":"Damage in lupus patients\u2013what have we learned so far","volume":"22","author":"Eder","year":"2013","journal-title":"Lupus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus. In: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"103374","DOI":"10.1016\/j.autrev.2023.103374","article-title":"Organ damage in Systemic Lupus Erythematosus patients: A multifactorial phenomenon","volume":"22","author":"Ceccarelli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/2040622310380100","article-title":"Contemporary treatment of systemic lupus erythematosus: an update for clinicians","volume":"1","author":"Amissah-Arthur","year":"2010","journal-title":"Ther Adv Chronic Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.3117","article-title":"update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.150","article-title":"The role of antimalarial agents in the treatment of SLE and lupus nephritis","volume":"7","author":"Lee","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221295","article-title":"Flares after hydroxychloroquine reduction or discontinuation. In: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Almeida-Brasil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: What have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1159794\/full","article-title":"Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review","volume":"10","author":"Sans-Pola","year":"2023","journal-title":"Front Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.12865\/CHSJ.44.03.18","article-title":"Therapy side effects in systemic lupus erythematosus","volume":"44","author":"Popa","year":"2018","journal-title":"Curr Health Sci J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7674","DOI":"10.1038\/s41598-024-58391-2","article-title":"Effect of hydroxychloroquine blood concentration on the efficacy and ocular toxicity of systemic lupus erythematosus","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000253","article-title":"Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis","volume":"5","author":"Tian","year":"2018","journal-title":"Lupus Sci Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.5.1955","article-title":"Peptide inhibition of glomerular deposition of an anti-DNA antibody","volume":"94","author":"Gaynor","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510055103","article-title":"Immunity and behavior: antibodies alter emotion","volume":"103","author":"Huerta","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2796.2010.02318.x","article-title":"Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus","volume":"269","author":"Diamond","year":"2011","journal-title":"J Intern Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1084\/jem.188.1.29","article-title":"Immunization with a peptide surrogate for double-stranded DNA (dsDNA) induces autoantibody production and renal immunoglobulin deposition","volume":"188","author":"Putterman","year":"1998","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1103555108","article-title":"Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity","volume":"108","author":"Bloom","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.08.070","article-title":"A structural investigation of FISLE-412, a peptidomimetic compound derived from saquinavir that targets lupus autoantibodies","volume":"27","author":"He","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/chem.201701944","article-title":"\u03b2-hydroxy-tetrahydroquinolines from quinolines using chloroborane: synthesis of the peptidomimetic FISLE-412","volume":"23","author":"Altiti","year":"2017","journal-title":"Chemistry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12734","article-title":"A peptide mimic blocks the cross-reaction of anti-DNA antibodies with glomerular antigens","volume":"183","author":"Xia","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13075-019-2038-0","article-title":"ALW peptide ameliorates lupus nephritis in MRL\/lpr mice","volume":"21","author":"Wang","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M110.002857","article-title":"Targeting peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification","volume":"10","author":"Hoeppe","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/art.24501","article-title":"Autoimmune regulator controls T cell help for pathogenetic autoantibody production in collagen-induced arthritis","volume":"60","author":"Campbell","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302897","article-title":"Regulatory CD4+ T cells promote B cell anergy in murine lupus","volume":"192","author":"Liu","year":"2014","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313547110","article-title":"B cells are critical for autoimmune pathology in Scurfy mice","volume":"110","author":"Aschermann","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1201131109","article-title":"Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo","volume":"109","author":"Gotot","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.05.051","article-title":"Nuclear antigen-reactive CD4+ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys","volume":"99","author":"Abdirama","year":"2021","journal-title":"Kidney Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6801","article-title":"Major peptide autoepitopes for nucleosome-specific T cells of human lupus","volume":"104","author":"Lu","year":"1999","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196268","article-title":"B cell tolerance and targeted therapies in SLE","volume":"12","author":"Parodis","year":"2023","journal-title":"J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study","volume":"66","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02658","article-title":"Novel treatments in lupus","volume":"9","author":"Vukelic","year":"2018","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00159","article-title":"The regulatory T cell in active systemic lupus erythematosus patients: A systemic review and meta-analysis","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/ar2511","article-title":"Regulatory T cells in systemic lupus erythematosus: past, present and future","volume":"10","author":"Horwitz","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901163","article-title":"Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus","volume":"183","author":"Iikuni","year":"2009","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.806612","article-title":"Targeting regulatory T cells for therapy of lupus nephritis","volume":"12","author":"Venkatadri","year":"2022","journal-title":"Front Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00786","article-title":"Targeting regulatory T cells to treat patients with systemic lupus erythematosus","volume":"9","author":"Mizui","year":"2018","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308090028","article-title":"T-regulatory cells in systemic lupus erythematosus","volume":"17","author":"La Cava","year":"2008","journal-title":"Lupus"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.3.1451","article-title":"Suppression of disease in New Zealand Black\/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells","volume":"177","author":"Scalapino","year":"2006","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006031","article-title":"Suppression of glomerulonephritis in NZB\/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells","volume":"4","author":"Scalapino","year":"2009","journal-title":"PloS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/ar4188","article-title":"CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice","volume":"15","author":"Weigert","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41467-024-45056-x","article-title":"Smith-specific regulatory T cells halt the progression of lupus nephritis","volume":"15","author":"Eggenhuizen","year":"2024","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2023-0021","article-title":"Low-dose interleukin-2 therapy in systemic lupus erythematosus","volume":"4","author":"La Cava","year":"2023","journal-title":"Rheumatol Immunol Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83323","article-title":"Efficacy and safety of low-dose interleukin-2 therapy in systemic lupus erythematosus: A systematic review","volume":"17","author":"Akkur","year":"2025","journal-title":"Cureus"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.02.001","article-title":"Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer","volume":"57","author":"Shouse","year":"2024","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80067-o","article-title":"Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene","volume":"75","author":"Sadlack","year":"1993","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1126\/science.7770771","article-title":"Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta","volume":"268","author":"Suzuki","year":"1995","journal-title":"Science"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3390\/cells8101234","article-title":"IL-2 therapy diminishes renal inflammation and the activity of kidney-infiltrating CD4+ T cells in murine lupus nephritis","volume":"8","author":"Rose","year":"2019","journal-title":"Cells"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110579","article-title":"Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus","volume":"69","author":"Alcocer-Varela","year":"1982","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B70","article-title":"Mixed results for rezpegaldesleukin in patients with active SLE","author":"Kaufman","year":"2023","journal-title":"Rheumatologist"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2014\/7903.4602","article-title":"Relationship between serum level of interleukin-2 in patients with systemic lupus erythematosus and disease activity in comparison with control group","volume":"8","author":"Sedighi","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400481","article-title":"IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R\/ST2+ regulatory T cells","volume":"193","author":"Matta","year":"2014","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.3390\/cells9112448","article-title":"Early treatment of interleukin-33 can attenuate lupus development in young NZB\/W F1 mice","volume":"9","author":"Mohd Jaya","year":"2020","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-013-9802-0","article-title":"IL-33 neutralization suppresses lupus disease in lupus-prone mice","volume":"37","author":"Li","year":"2014","journal-title":"Inflammation"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9104-0","article-title":"Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus","volume":"27","author":"Chun","year":"2007","journal-title":"J Clin Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nature06878","article-title":"TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function","volume":"453","author":"Zhou","year":"2008","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.02.013","article-title":"The weight of interleukin-6 in B cell-related autoimmune disorders","volume":"32","author":"Youinou","year":"2009","journal-title":"J Autoimmun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu1023oa","article-title":"Rationale for interleukin-6 blockade in systemic lupus erythematosus","volume":"13","author":"Tackey","year":"2004","journal-title":"Lupus"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/art.39722","article-title":"Placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3390","article-title":"Phosphatase PP2A is requisite for the function of regulatory T cells","volume":"17","author":"Apostolidis","year":"2016","journal-title":"Nat Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005994","article-title":"Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin","volume":"4","author":"Strauss","year":"2009","journal-title":"PloS One"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370219","article-title":"Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus","volume":"37","author":"Warner","year":"1994","journal-title":"Arthritis Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/art.22085","article-title":"Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00082","article-title":"Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus","volume":"10","author":"Eriksson","year":"2019","journal-title":"Front Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2014.915954","article-title":"KN-93, an inhibitor of calcium\/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3+ regulatory T cells in MRL\/lpr mice","volume":"47","author":"Koga","year":"2014","journal-title":"Autoimmunity"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501603","article-title":"Cutting edge: nanogel-based delivery of an inhibitor of caMK4 to CD4+ T cells suppresses experimental autoimmune encephalomyelitis and lupus-like disease in mice","volume":"195","author":"Otomo","year":"2015","journal-title":"J Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b09998","article-title":"MicroRNA-125a-loaded polymeric nanoparticles alleviate systemic lupus erythematosus by restoring effector\/regulatory T cells balance","volume":"14","author":"Zhang","year":"2020","journal-title":"ACS Nano"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200102)44:2<432::AID-ANR62>3.0.CO;2-S","article-title":"Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus","volume":"44","author":"Hahn","year":"2001","journal-title":"Arthritis Rheumatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08898-7","article-title":"The therapeutic strategies for SLE by targeting anti-dsDNA antibodies","volume":"63","author":"Wang","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.11.004","article-title":"Tolerance induced by anti-DNA Ig peptide in (NZB\u00d7NZW)F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells","volume":"142","author":"Yu","year":"2012","journal-title":"Clin Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/art.23609","article-title":"Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients","volume":"58","author":"Hahn","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1517\/14712590802681636","article-title":"Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus","volume":"9","author":"Iikuni","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02058.x","article-title":"Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies","volume":"131","author":"Sthoeger","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2023-0020","article-title":"Peptide-based immunotherapy in lupus: Where are we now","volume":"4","author":"Singh","year":"2023","journal-title":"Rheumatol Immunol Res"},{"key":"B97","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0603201103","article-title":"A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta","volume":"103","author":"Sharabi","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000104","article-title":"Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study","volume":"2","author":"Urowitz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.6.3247","article-title":"Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets","volume":"174","author":"Kang","year":"2005","journal-title":"J Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901773","article-title":"Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus","volume":"183","author":"Zhang","year":"2009","journal-title":"J Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.08.008","article-title":"Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity","volume":"149","author":"Zhang","year":"2013","journal-title":"Clin Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.2.1126","article-title":"Histone peptide-induced nasal tolerance: suppression of murine lupus","volume":"169","author":"Wu","year":"2002","journal-title":"J Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1191\/0961203303lu1002oa","article-title":"A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen","volume":"13","author":"Wu","year":"2004","journal-title":"Lupus"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310389484","article-title":"Novel peptides as potential treatment of systemic lupus erythematosus","volume":"20","author":"Shapira","year":"2011","journal-title":"Lupus"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.12.8392","article-title":"Global natural regulatory T cell depletion in active systemic lupus erythematosus","volume":"175","author":"Miyara","year":"2005","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307080226","article-title":"Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus","volume":"16","author":"Barath","year":"2007","journal-title":"Lupus"},{"key":"B107","article-title":"Expression of intracellular transforming growth factor-beta1 in CD4+CD25+ cells in patients with systemic lupus erythematosus","volume":"41","author":"Lu","year":"2008","journal-title":"J Microbiol Immunol Infect"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxn044","article-title":"Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE)","volume":"20","author":"Bonelli","year":"2008","journal-title":"Int Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/art.24499","article-title":"Th17 and natural Treg cell population dynamics in systemic lupus erythematosus","volume":"60","author":"Yang","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2567.2008.02937.x","article-title":"Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus","volume":"127","author":"Suen","year":"2009","journal-title":"Immunology"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1407","article-title":"CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study","volume":"32","author":"Tselios","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00005-016-0399-5","article-title":"CD4(+)CD25(+)CD127(-) and CD4(+)CD25(+)Foxp3(+) regulatory T cell subsets in mediating autoimmune reactivity in systemic lupus erythematosus patients","volume":"64","author":"\u017babi\u0144ska","year":"2016","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cellimm.2010.05.004","article-title":"Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus","volume":"264","author":"Henriques","year":"2010","journal-title":"Cell Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/art.23556","article-title":"Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -\/low regulatory T cells in patients with active systemic lupus erythematosus","volume":"58","author":"Venigalla","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"58(3)","DOI":"10.1002\/art.23268","article-title":"Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells","author":"Yan","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3197-x","article-title":"Vitamin A improve Th17 and Treg regulation in systemic lupus erythematosus","volume":"35","author":"Handono","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13050","article-title":"CD4+ T helper cells and regulatory T cells in active lupus nephritis: an imbalance towards a predominant Th1 response","volume":"191","author":"Mesquita","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B118","volume-title":"Immunobiology: the immune system in health and disease","author":"Janeway","year":"2001"},{"key":"B119","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.immuni.2007.12.004","article-title":"Sites and stages of autoreactive B cell activation and regulation","volume":"28","author":"Shlomchik","year":"2008","journal-title":"Immunity"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78083","article-title":"Checkpoints that control B cell development","volume":"125","author":"Melchers","year":"2015","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0065-2776(07)95003-8","article-title":"B-cell self-tolerance in humans","volume":"95","author":"Wardemann","year":"2007","journal-title":"Adv Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/science.2356469","article-title":"The need for central and peripheral tolerance in the B cell repertoire","volume":"248","author":"Goodnow","year":"1990","journal-title":"Science"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050221","article-title":"Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus","volume":"202","author":"Jacobi","year":"2005","journal-title":"J Exp Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.10.007","article-title":"B cells and autoimmunity","volume":"23","author":"Pillai","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231314","article-title":"B cell tolerance and autoimmunity: Lessons from repertoires","volume":"221","author":"Deguine","year":"2024","journal-title":"J Exp Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.4.1009","article-title":"Receptor editing in self-reactive bone marrow B cells","volume":"177","author":"Tiegs","year":"1993","journal-title":"J Exp Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1084\/jem.177.4.999","article-title":"Receptor editing: an approach by autoreactive B cells to escape tolerance","volume":"177","author":"Gay","year":"1993","journal-title":"J Exp Med"},{"key":"B130","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.13070","article-title":"Role of inhibitory signaling in peripheral B cell tolerance","volume":"307","author":"Getahun","year":"2022","journal-title":"Immunol Rev"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031498","article-title":"Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen","volume":"198","author":"Song","year":"2003","journal-title":"J Exp Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1126\/science.1073924","article-title":"Evolution of autoantibody responses via somatic hypermutation outside of germinal centers","volume":"297","author":"William","year":"2002","journal-title":"Science"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.5.2019","article-title":"Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease","volume":"93","author":"Ray","year":"1996","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.2.461","article-title":"Somatic mutations in the variable regions of a human IgG anti-double-stranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus","volume":"173","author":"van Es","year":"1991","journal-title":"J Exp Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220709","article-title":"Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas","volume":"22","author":"Winkler","year":"1992","journal-title":"Eur J Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500132102","article-title":"The evolution of human anti-double-stranded DNA autoantibodies","volume":"102","author":"Wellmann","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803644105","article-title":"Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors","volume":"105","author":"Mietzner","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20092712","article-title":"Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity","volume":"207","author":"Guo","year":"2010","journal-title":"J Exp Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/328805a0","article-title":"The role of clonal selection and somatic mutation in autoimmunity","volume":"328","author":"Shlomchik","year":"1987","journal-title":"Nature"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12741","article-title":"Extrafollicular responses in humans and SLE","volume":"288","author":"Jenks","year":"2019","journal-title":"Immunol Rev"},{"key":"B141","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.imlet.2023.03.003","article-title":"IgD-CD27- double negative (DN) B cells: Origins and functions in health and disease","volume":"255","author":"Beckers","year":"2023","journal-title":"Immunol Lett"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217341","article-title":"Functions of double-negative B cells in autoimmune diseases, infections, and cancers","volume":"15","author":"Chung","year":"2023","journal-title":"EMBO Mol Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.602539","article-title":"Single-cell transcriptomic analyses define distinct peripheral B cell subsets and discrete development pathways","volume":"12","author":"Stewart","year":"2021","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","article-title":"Toll-like receptor signalling in B cells during systemic lupus erythematosus","volume":"17","author":"Fillatreau","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated B cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.jtauto.2024.100252","article-title":"Extrafollicular CD19lowCXCR5-CD11c- double negative 3 (DN3) B cells are significantly associated with disease activity in females with systemic lupus erythematosus","volume":"9","author":"Chizzolini","year":"2024","journal-title":"J Transl Autoimmun"},{"key":"B148","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1038\/s41467-023-39734-5","article-title":"Toll-like receptor mediated inflammation directs B cells towards protective antiviral extrafollicular responses","volume":"14","author":"Lam","year":"2023","journal-title":"Nat Commun"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70005","article-title":"Innate immune receptors as dynamic modulators of extrafollicular autoimmune B cell response","volume":"330","author":"Zhu","year":"2025","journal-title":"Immunol Rev"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00852","article-title":"The differentiation in vitro of human tonsil B cells with the phenotypic and functional characteristics of T-bet+ Atypical memory B cells in malaria","volume":"10","author":"Ambegaonkar","year":"2019","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg8384","article-title":"Shared transcriptional profiles of atypical B cells suggest common drivers of expansion and function in malaria, HIV, and autoimmunity","volume":"7","author":"Holla","year":"2021","journal-title":"Sci Adv"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.06.010","article-title":"Selective silencing of autoreactive B lymphocytes\u2014Following the Nature\u2019s way","volume":"9","author":"Nikolova","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/290257a0","article-title":"Idiotypic regulation by isologous monoclonal anti-idiotope antibodies","volume":"290","author":"Reth","year":"1981","journal-title":"Nature"},{"key":"B154","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/096120339400300110","article-title":"Injections of complexes made of dsDNA and specific polyclonal antibodies extend MRL lpr mouse survival: a pilot study","volume":"3","author":"Lebrun","year":"1994","journal-title":"Lupus"},{"key":"B155","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/096120339700600102","article-title":"Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice","volume":"6","author":"Burny","year":"1997","journal-title":"Lupus"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1126\/science.6231724","article-title":"Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen","volume":"224","author":"Celis","year":"1984","journal-title":"Science"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902946419","article-title":"Abetimus sodium: a medication for the prevention of lupus nephritis flares","volume":"10","author":"Horowitz","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.6.873","article-title":"LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus","volume":"8","author":"Mosca","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"B159","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.rdc.2005.11.001","article-title":"Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus","volume":"32","author":"Furie","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/art.23673","article-title":"LJP 394-90\u201309 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial","volume":"58","author":"Cardiel","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5489.84","article-title":"Immune inhibitory receptors","volume":"290","author":"Ravetch","year":"2000","journal-title":"Science"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101194","article-title":"The inhibiting Fc receptor for IgG, Fc\u03b3RIIB, is a modifier of autoimmune susceptibility","volume":"187","author":"Boross","year":"2011","journal-title":"J Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364423","article-title":"Expression of the autoimmune Fcgr2b NZW allele fails to be upregulated in germinal center B cells and is associated with increased IgG production","volume":"8","author":"Rahman","year":"2007","journal-title":"Genes Immun"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.1.187","article-title":"Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis","volume":"189","author":"Yuasa","year":"1999","journal-title":"J Exp Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1084\/jem.191.5.899","article-title":"Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease","volume":"191","author":"Nakamura","year":"2000","journal-title":"J Exp Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)00027-3","article-title":"Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis","volume":"13","author":"Bolland","year":"2000","journal-title":"Immunity"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121752","article-title":"Analysis of a wild mouse promoter variant reveals a novel role for Fc\u03b3RIIb in the control of the germinal center and autoimmunity","volume":"209","author":"Esp\u00e9li","year":"2012","journal-title":"J Exp Med"},{"key":"B168","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/ni1151","article-title":"The inhibitory Fc\u03b3 receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells","volume":"6","author":"Fukuyama","year":"2005","journal-title":"Nat Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1002\/art.40555","article-title":"The lupus-associated fc\u03b3 Receptor IIb-I232T polymorphism results in impairment in the negative selection of low-affinity germinal center B cells via c-abl in mice","volume":"70","author":"Jhou","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/11.10.1685","article-title":"Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus","volume":"11","author":"Jiang","year":"1999","journal-title":"Int Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100171","article-title":"Development of self-reactive germinal center B cells and plasma cells in autoimmune Fc gammaRIIB-deficient mice","volume":"207","author":"Tiller","year":"2010","journal-title":"J Exp Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157250","article-title":"Fc\u03b3RIIB regulates autoantibody responses by limiting marginal zone B cell activation","volume":"132","author":"Barlev","year":"2022","journal-title":"J Clin Invest"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1126\/science.1105160","article-title":"Restoration of tolerance in lupus by targeted inhibitory receptor expression","volume":"307","author":"McGaha","year":"2005","journal-title":"Science"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072565","article-title":"Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb","volume":"205","author":"Brownlie","year":"2008","journal-title":"J Exp Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737143","article-title":"Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL\/lpr mice","volume":"37","author":"Tchorbanov","year":"2007","journal-title":"Eur J Immunol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.5.2530","article-title":"Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus","volume":"168","author":"Kaliyaperumal","year":"2002","journal-title":"J Immunol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm133","article-title":"Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc\u03b3IIb receptor","volume":"20","author":"Mihaylova","year":"2008","journal-title":"Int Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12164","article-title":"Targeted silencing of DNA-specific B cells combined with partial plasma cell depletion displays additive effects on delaying disease onset in lupus-prone mice","volume":"174","author":"Nikolova-Ganeva","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2007.12.016","article-title":"An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes","volume":"116","author":"Voynova","year":"2008","journal-title":"Immunol Lett"},{"key":"B180","doi-asserted-by":"publisher","first-page":"109624","DOI":"10.1016\/j.celrep.2021.109624","article-title":"SMS2 deficiency impairs PKC\u03b4-regulated B cell tolerance in the germinal center","volume":"36","author":"Ou","year":"2021","journal-title":"Cell Rep"},{"key":"B181","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/sj.emboj.7600034","article-title":"Identification of a family of animal sphingomyelin synthases","volume":"23","author":"Huitema","year":"2004","journal-title":"EMBO J"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/nature02955","article-title":"Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling","volume":"431","author":"Mecklenbr\u00e4uker","year":"2004","journal-title":"Nature"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.151","article-title":"Platelet-derived growth factor activates protein kinase C epsilon through redundant and independent signaling pathways involving phospholipase C gamma or phosphatidylinositol 3-kinase","volume":"93","author":"Moriya","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201747102","article-title":"PKC\u03f5 promotes human Th17 differentiation: Implications in the pathophysiology of psoriasis","volume":"48","author":"Martini","year":"2018","journal-title":"Eur J Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2016","article-title":"STIM1, PKC-\u03b4 and RasGRP set a threshold for proapoptotic Erk signaling during B cell development","volume":"12","author":"Limnander","year":"2011","journal-title":"Nat Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01699-13","article-title":"Protein kinase C\u03b4 promotes transitional B cell-negative selection and limits proximal B cell receptor signaling to enforce tolerance","volume":"34","author":"Limnander","year":"2014","journal-title":"Mol Cell Biol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1002\/art.38008","article-title":"Protein kinase C\u03b4 Deficiency causes mendelian systemic lupus erythematosus with B cell\u2013defective apoptosis and hyperproliferation","volume":"65","author":"Belot","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-469544","article-title":"Loss-of-function of the protein kinase C \u03b4 (PKC\u03b4) causes a B-cell lymphoproliferative syndrome in humans","volume":"121","author":"Kuehn","year":"2013","journal-title":"Blood"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-460741","article-title":"B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C \u03b4","volume":"121","author":"Salzer","year":"2013","journal-title":"Blood"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/biomedicines12061364","article-title":"PKC\u03b4 Protects against lupus autoimmunity","volume":"12","author":"Chavan","year":"2024","journal-title":"Biomedicines"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/197197a0","article-title":"Renal disease associated with positive lupus erythematosus tests in a crossbred strain of mice","volume":"197","author":"Helyer","year":"1963","journal-title":"Nature"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.051","article-title":"A conserved circular network of coregulated lipids modulates innate immune responses","volume":"162","author":"K\u00f6berlin","year":"2015","journal-title":"Cell"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400098","article-title":"Opposing impact of B cell intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation","volume":"192","author":"Jackson","year":"2014","journal-title":"J Immunol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132328","article-title":"B cell-intrinsic TLR9 expression is protective in murine lupus","volume":"130","author":"Tilstra","year":"2020","journal-title":"J Clin Invest"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172219","article-title":"B cell-intrinsic TLR7 expression drives severe lupus in TLR9-deficient mice","volume":"8","author":"Cosgrove","year":"2023","journal-title":"JCI Insight"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"B197","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B198","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J Immunol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11926-012-0258-2","article-title":"The rationale for BAFF inhibition in systemic lupus erythematosus","volume":"14","author":"Davidson","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2005.01.014","article-title":"Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells","volume":"33","author":"Kaur","year":"2005","journal-title":"Exp Hematol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109671200","article-title":"Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727","volume":"277","author":"Uddin","year":"2002","journal-title":"J Biol Chem"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.267","article-title":"Activation of protein kinase C delta by IFN-gamma","volume":"171","author":"Deb","year":"2003","journal-title":"J Immunol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L","article-title":"Inhibition of T cell apoptosis by IFN-beta rapidly reverses nuclear translocation of protein kinase C-delta","volume":"29","author":"Scheel-Toellner","year":"1999","journal-title":"Eur J Immunol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.07.012","article-title":"Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs","volume":"27","author":"Xie","year":"2007","journal-title":"Immunity"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02356-1","article-title":"A Phase 1\/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma","volume":"129","author":"Lopez","year":"2023","journal-title":"Br J Cancer"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1115484108","article-title":"Sphingomyelin and sphingomyelin synthase (SMS) in the Malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy","volume":"108","author":"Barcel\u00f3-Coblijn","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1118349109","article-title":"2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy","volume":"109","author":"Ter\u00e9s","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M036749","article-title":"Sustained activation of sphingomyelin synthase by 2-hydroxyoleic acid induces sphingolipidosis in tumor cells","volume":"54","author":"Martin","year":"2013","journal-title":"J Lipid Res"},{"key":"B210","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/membranes11100787","article-title":"Hydroxylated fatty acids: the role of the sphingomyelin synthase and the origin of selectivity","volume":"11","author":"Sessa","year":"2021","journal-title":"Membranes (Basel)"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.005904","article-title":"2-Hydroxy-oleic acid does not activate sphingomyelin synthase activity","volume":"293","author":"Lou","year":"2018","journal-title":"J Biol Chem"},{"key":"B212","doi-asserted-by":"publisher","first-page":"107960","DOI":"10.1016\/j.jbc.2024.107960","article-title":"Multiple activities of sphingomyelin synthase 2 generate saturated fatty acid- and\/or monounsaturated fatty acid-containing diacylglycerol","volume":"300","author":"Murakami","year":"2024","journal-title":"J Biol Chem"},{"key":"B213","doi-asserted-by":"publisher","first-page":"101398","DOI":"10.1016\/j.jbc.2021.101398","article-title":"Sphingomyelin synthases 1 and 2 exhibit phosphatidylcholine phospholipase C activity","volume":"297","author":"Chiang","year":"2021","journal-title":"J Biol Chem"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14735","article-title":"Human sphingomyelin synthase 1 generates diacylglycerol in the presence and absence of ceramide via multiple enzymatic activities","volume":"597","author":"Suzuki","year":"2023","journal-title":"FEBS Lett"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-019-00549-8","article-title":"High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C